Congress Materials – International Society for Heart & Lung Transplantation (ISHLT 2025)
2025 International Society for Heart & Lung Transplantation | Apr 27-30 | Boston, MA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Early initiation of selexipag for pulmonary arterial hypertension (PAH): Real-world evidence from the EXPOSURE/EXTRACT studies
Sean Gaine, Pilar Escribano-Subias, Audrey Muller, Julian I. Borissoff, Catarina C. Fernandes, Martina Fontana, Tatiana Remeňová, Tobias J. Lange, Stefan Söderberg
Healthcare resource utilization and progression in patients with pulmonary arterial hypertension initiated on monotherapy with macitentan versus other endothelin-receptor antagonists
Carly J. Paoli, Louise Huafeng Yu, Ambika Satija, Sherry Shi, Béatrice Libchaber, Marjolaine Gauthier-Loiselle, Sumeet Panjabi
10-year data on oral selexipag: long-term survival, safety, and dosing insights in pulmonary arterial hypertension (PAH) from the GRIPHON study and its open-label extension (OLE)
Vallerie V. McLaughlin, Luke Howard, Jean Elwing, Catarina C. Fernandes, Sean Gaine, Nazzareno Galiè, Nicolas Martin, Ronald J Oudiz, Paul Strachan, Yuichi Tamura, Nick H. Kim
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.